25 results
424B5
BLPH
Bellerophon Therapeutics, Inc.
20 May 20
Prospectus supplement for primary offering
4:03pm
Phase 2 clinical trial of INOpulse for PAH. The data reinforced the results from October 2014 and indicated a sustainability of benefit to PAH patients
424B5
BLPH
Bellerophon Therapeutics, Inc.
20 May 20
Prospectus supplement for primary offering
4:02pm
and indicated a sustainability of benefit to PAH patients who received INOpulse therapy at the 75 mcg dose for an average of greater than 12 hours per day
424B5
ak1a4op4lobjneozm hz
18 May 20
Prospectus supplement for primary offering
4:02pm
424B5
zaqtqxcik
31 Mar 20
Prospectus supplement for primary offering
7:03am
424B5
gvknt4atttkhlpk350
23 Jan 19
Prospectus supplement for primary offering
5:14pm
424B5
3gfzjx4pqw
23 Jan 19
Prospectus supplement for primary offering
12:00am
424B2
zc951bmexf2sksa dg7o
17 Jul 18
Prospectus for primary offering
4:26pm